Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format



    AURORA, ON, Jan. 16 /CNW/ - Helix BioPharma Corp. (TSX: HBP/Frankfurt:
WKN 918846) announced today that it has signed an agreement with KBI Biopharma
Inc. ("KBI") to develop a process for preparing L-DOS47 in a lyophilized
(freeze-dried powder) vial format suitable for clinical testing.
    "This new arrangement advances the Company closer to its objective of
initiating clinical testing with L-DOS47," said John Docherty, Helix's
president. "The lyophilized packaging format will provide for optimum
stability of L-DOS47 while in storage so that individual vials may be
reconstituted in liquid form immediately prior to patient administration."

    About L-DOS47

    L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody to form a potential new targeted drug
product for the treatment of adenocarcinoma of the lung, the most common form
of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle to produce an anti-cancer
effect. It is based upon a naturally occurring enzyme called urease that
essentially reverses the urea cycle by breaking down urea into metabolites
that include ammonia and hydroxyl ions. By doing so at the site of cancerous
tissues in the body, L-DOS47 is believed to modify the microenvironmental
conditions of lung cancer cells in a manner that leads to their death. Among
these theorized effects, L-DOS47 is believed to stimulate an increase in the
pH of the microenvironment surrounding the cancerous cells, effectively
reversing the acidic extra-cellular conditions that are known to be necessary
for cancer cell survival. As well, the local production of ammonia at the site
of cancerous tissues is thought to readily diffuse into the cancer cells to
exert a potent cytotoxic effect by interfering with their critical metabolic
functions. Helix intends to seek approval in 2008 by the U.S. Food and Drug
Administration ("FDA") to conduct a Phase I clinical study with L-DOS47 in
lung adenocarcinoma patients.

    About KBI BioPharma

    KBI Biopharma Inc. is a contract biopharmaceutical development
organization offering a full range of preformulation/formulation development,
analytical method development and validation, full process development and
clinical manufacturing (for both mammalian and microbial programs). Services
are carried out in state-of-the-art laboratories housed in Durham, North
Carolina. More information can be obtained from www.kbibiopharma.com.

    About Helix BioPharma Corp.

    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed
on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich
and Stuttgart Stock Exchanges under the same symbol.

    The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this News
Release. Helix has relied solely on KBI Biopharma for the information about
KBI Biopharma provided in this News Release and Helix disclaims any liability
with respect to such information. Helix disclaims responsibility for
information contained in any linked or referenced website, and such links and
references do not constitute an endorsement by Helix of those or any other
website. This News Release contains forward-looking statements and information
regarding production of L-DOS47, a planned Phase I clinical study, and
products under development, which statements can be identified by the words
"will", "potential", "is thought", "is believed", "intends", and "developing".
Actual results or events could differ materially from these forward-looking
statements and information due to numerous factors, including without
limitation, the risk that the contract with KBI Biopharma may be terminated
early; reliance on KBI Biopharma for performance; uncertainty whether FDA
approval will be sought as anticipated or at all, or if sought, whether FDA
approval will be granted; uncertainty whether the planned Phase I clinical
trial will commence or complete as anticipated or will deliver positive
results; research & development risks, intellectual property risks; product
liability risks; the risk of unanticipated expenses, and possible changes in
business strategy or plans. These and other risks and uncertainties are
contained in Helix's latest Annual Information Form at www.sedar.com.
Forward-looking statements and information are based on the assumptions and
expectations of Helix's management at the time they are made, and Helix does
not assume any obligation, except as required by law, to update any
forward-looking statement or information should those assumptions or
expectations, or other circumstances change.





For further information:

For further information: Investor Relations: Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, 1-800-385-5451, Fax: (416)
815-0080, Email: cbessant@equicomgroup.com; Media Relations: David Schull,
Russo Partners LLC, Tel: (212) 845-4271, Fax: (212) 845-4260, Email:
David.Schull@russopartnersllc.com, www.russopartnersllc.com

Organization Profile

HELIX BIOPHARMA CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890